The G1691A mutation of the factor V gene (factor V Leiden) and the G20210A mutation of the prothrombin gene as risk factors in thrombotic microangiopathies
| Autor: | Bernd Grabensee, Christine Kurschat, Ruediger E. Scharf, Ljerka Ostojic, Rainer B. Zotz, Gerd R. Hetzel, Robert Loncar, Christoph Sucker, Beate Maruhn-Debowski |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
medicine.medical_specialty Heterozygote DNA Mutational Analysis Gastroenterology Young Adult Risk Factors Internal medicine medicine Factor V Leiden Thrombotic Microangiopathies Humans Genetic Predisposition to Disease Gene Aged biology Prothrombin mutation Purpura Thrombotic Thrombocytopenic business.industry Factor V Hematology General Medicine Middle Aged medicine.disease Venous thrombosis Increased risk Case-Control Studies Mutation (genetic algorithm) Hemolytic-Uremic Syndrome Mutation biology.protein Prothrombin business |
| Zdroj: | Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 15(3) |
| ISSN: | 1076-0296 |
| Popis: | Factor V Leiden (FVL) mutation and prothrombin G20210A mutation are common hereditary risk factors for venous thrombosis. In the current study, 40 patients (mean age ± standard deviation, 35 ± 11 years) and 764 healthy control subjects (mean age ± standard deviation, 37 ± 14 years) were enrolled to assess the potential role of these mutations in the manifestation of thrombotic microangiopathies. Compared with controls, neither the heterozygous FVL mutation (7.5% vs 8.5%; P = 1) nor the heterozygous prothrombin mutation (2.5% vs 2.8%; P = 1) was more prevalent in the patients. The findings do not support a significant role of FVL and prothrombin mutations as risk factors for the manifestation of thrombotic microangiopathies. Thus, screening for these mutations does not allow the identification of individuals at increased risk for these rare thrombotic disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|